Possible Side Effects or Concerns Nausea, diarrhea, headache, or an unpleasant taste Acneiform or rosacea-like eruptions reported in some people using high doses Allergic reaction to cobalt, B12, flavoring, dye, preservative, or another ingredient Incorrect dosing caused by confusing drops, droppers, milliliters, and micrograms Delayed diagnosis when fatigue or neurologic symptoms are assumed to be just low B12 Misinterpretation of a high blood B12 level after supplementation Medicine and Health Considerations Metformin and gastric acid inhibitors can lower B12 status over time
"Once-weekly semaglutide 2.0 mg versus 1.0 mg in type 2 diabetes." Lancet Diabetes Endocrinol
Scientific References (External Links) Drug Testing and Analysis: Detection and in vitro metabolism of AOD9604 View Study Endocrinology: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice View Study Hormone Research: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone View Study Current Opinion in Investigational Drugs: AOD-9604 Metabolic View Study
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
Forbes, J., & Krishnamurthy, K
defense substances, against this relevant binding protein TC II is considered to be a possible cause (Takahashi et al., 2013)
